AI in Pharma Projected to Hit $28.6B by 2034 as Drug Discovery Push Accelerates
New market research puts AI in pharmaceuticals on track for $28.6 billion by 2034, with Asia-Pacific the fastest-growing region as discovery pipelines and trial operations absorb the technology.
The market for artificial intelligence in pharmaceuticals is projected to reach $28.6 billion by 2034, according to research highlighted by Healthcare Asia, as drug discovery moves from AI pilots to AI-native pipelines.
Where the money goes
Discovery remains the anchor use case — molecule generation, target identification and protein structure work — but the growth is broadening into clinical operations: trial design, patient recruitment, pharmacovigilance and regulatory documentation. The through-line is time: every month shaved off a development cycle is worth more than the software costs.
The Asia-Pacific angle
Asia-Pacific is expected to be the fastest-growing region over the forecast period. The drivers are structural — large patient populations generating trial data, government AI-in-health programs in China, Japan, Korea and Singapore, and contract research organizations across the region emb
Newsletter
Get Lanceum in your inbox
Weekly insights on AI and technology in Asia.
